Cibc World Market Inc. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 84.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 120,866 shares of the medical research company’s stock after purchasing an additional 55,181 shares during the quarter. Cibc World Market Inc.’s holdings in Amgen were worth $50,946,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in AMGN. BlackRock Inc. raised its holdings in shares of Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after acquiring an additional 2,261,544 shares during the period. State Street Corp increased its position in Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Amgen by 12.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock worth $1,952,156,000 after purchasing an additional 605,928 shares during the last quarter. Bank of America Corp DE purchased a new position in Amgen during the second quarter worth about $1,831,903,000. Finally, Amundi boosted its holdings in Amgen by 15.2% in the 2nd quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock valued at $1,408,715,000 after purchasing an additional 512,883 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
AMGN has been the subject of several analyst reports. TD Cowen increased their price target on shares of Amgen from $452.00 to $531.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Mizuho upped their price objective on Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a report on Tuesday, August 18th. Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, October 18th. Sanford C. Bernstein increased their price objective on Amgen from $345.00 to $400.00 and gave the stock a “market perform” rating in a research report on Wednesday, November 4th. Finally, BMO Capital Markets cut their target price on Amgen from $450.00 to $415.00 and set a “market perform” rating for the company in a research note on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $425.69.
Get Our Latest Stock Analysis on Amgen
Amgen Trading Down 0.9%
Shares of AMGN stock opened at $457.93 on Wednesday. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. The firm has a market cap of $247.70 billion, a PE ratio of 26.56, a price-to-earnings-growth ratio of 3.22 and a beta of 0.43. The company has a 50-day moving average of $427.10 and a two-hundred day moving average of $382.34. Amgen Inc. has a 1-year low of $312.39 and a 1-year high of $483.99.
Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The business had revenue of $10.37 billion during the quarter, compared to analysts’ expectations of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period last year, the business earned $5.64 earnings per share. On average, analysts predict that Amgen Inc. will post 23.37 EPS for the current year.
Amgen Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. Amgen’s dividend payout ratio (DPR) is presently 58.47%.
Amgen News Roundup
Investors following AMGN have been watching these news items:
- Positive Sentiment: Amgen has raised its 2026 outlook twice, with newer products helping offset pressure on Prolia and XGEVA. A broader biotech-industry report also cites strong 2026 results and raised outlooks among leading companies, including Amgen. Amgen outlook and product pressures Biotechnology market outlook
- Positive Sentiment: Amgen’s obesity-treatment candidate is described as a potential rival in a market led by Novo Nordisk, offering a possible future growth opportunity. Novo Nordisk versus Amgen
- Negative Sentiment: Prolia and XGEVA face falling sales under biosimilar competition, a headwind that makes continued growth in newer medicines important. Barclays maintained an “equal weight”/Hold view despite raising its target to $430, below the stock’s quoted $457.93 level. Barclays maintains Hold rating
Amgen Company Profile
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Featured Articles
- Five stocks we like better than Amgen
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
